Trial Profile
Protocol CC100A CC100: Safety and Tolerability of Single Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs CC 100 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Chemigen
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jul 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 01 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.